Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MQ710 |
Synonyms | |
Therapy Description |
MQ710 is a cancer vaccine comprising a modified vaccinia virus Ankara engineered with deletion of the viral E5R gene and to express FLT3L and OX40L, which potentially increases interferon signaling and cytokine release, reduces immunosuppression, and enhances antitumor immune response (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MQ710 | MQ-710|MQ 710 | MQ710 is a cancer vaccine comprising a modified vaccinia virus Ankara engineered with deletion of the viral E5R gene and to express FLT3L and OX40L, which potentially increases interferon signaling and cytokine release, reduces immunosuppression, and enhances antitumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05859074 | Phase I | MQ710 + Pembrolizumab MQ710 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | Active, not recruiting | USA | 0 |